Cardlytics, Inc. (NASDAQ:CDLX) Shares Acquired by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD lifted its holdings in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 59.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 62,471 shares of the company’s stock after purchasing an additional 23,197 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.12% of Cardlytics worth $232,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Mirabella Financial Services LLP acquired a new position in Cardlytics in the fourth quarter valued at $4,285,000. Geode Capital Management LLC boosted its holdings in Cardlytics by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,060,739 shares of the company’s stock valued at $3,936,000 after acquiring an additional 7,561 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Cardlytics by 3.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 402,552 shares of the company’s stock valued at $1,493,000 after acquiring an additional 12,209 shares during the last quarter. Rangeley Capital LLC acquired a new position in Cardlytics in the fourth quarter valued at $1,187,000. Finally, Brooktree Capital Management boosted its holdings in Cardlytics by 4.5% in the fourth quarter. Brooktree Capital Management now owns 175,210 shares of the company’s stock valued at $650,000 after acquiring an additional 7,568 shares during the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

Cardlytics Trading Up 3.5%

Shares of CDLX opened at $2.06 on Friday. The stock’s 50-day moving average is $1.81 and its two-hundred day moving average is $2.91. The stock has a market cap of $108.15 million, a PE ratio of -0.34 and a beta of 1.30. Cardlytics, Inc. has a 12 month low of $1.22 and a 12 month high of $9.85. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18.

Insiders Place Their Bets

In related news, CEO Amit Gupta sold 46,857 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $159,313.80. Following the transaction, the chief executive officer now owns 418,637 shares in the company, valued at approximately $1,423,365.80. The trade was a 10.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Alexis Desieno sold 24,778 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $84,245.20. Following the completion of the transaction, the chief financial officer now owns 140,948 shares in the company, valued at approximately $479,223.20. This trade represents a 14.95% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,938 shares of company stock worth $244,017 over the last quarter. 4.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on CDLX shares. Lake Street Capital reduced their target price on Cardlytics from $3.00 to $2.50 and set a “hold” rating on the stock in a report on Thursday, May 8th. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a report on Thursday, March 13th. Finally, Evercore ISI reduced their target price on Cardlytics from $4.00 to $3.00 and set an “in-line” rating on the stock in a report on Thursday, March 13th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.20.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.